Michael Bauer currently serves as the COO at Microsize, a position held since July 2022. Prior to this role, Michael was the Site Head at Lonza Quakertown from 2018 to July 2022 and held the title of General Manager at Powdersize, LLC from November 2015 to 2018. Michael's career at Powdersize, Inc. spanned from September 2003 to November 2015, where Michael worked as the Laboratory/Quality Manager. Michael holds a Bachelor of Science degree in Materials Engineering from Lehigh University, earned between 1999 and 2003.
This person is not in any teams
Microsize (Micronization, Particle Size Engineering, Pharmaceutical Development)
Microsize specializes in Particle Size Reduction, Powder Classification, and Analytical Services, catering to a diverse clientele, including small biotechs, Big Pharma, CDMOs (API, Dosage Form, Integrated), and Functional Excipient Companies. Our expertise in milling and micronization processes enables us to develop and manufacture products with unique physical property challenges. We offer high-turn feasibility studies within our development suites, requiring as little as 1-5 grams of API. For highly potent compounds, including cytotoxics (HPAPIs), we provide world-class high containment infrastructure in our R&D labs and GMP suites to match your development stage. Our solutions cover Small Molecule APIs and HPAPIs, Functional Excipients, NCEs, 505b2s, and Generics. We support every phase of development, from Discovery and Phases I-III to Commercial Launch and Generic production. As North America's largest independent pharmaceutical micronization business, Microsize is a pioneer in enhancing dissolution and bioavailability of Active Pharmaceutical Ingredients (APIs). We rapidly develop, scale-up, and process APIs and excipients from grams to multi-metric tons, including highly potent compounds. Choose Microsize as your trusted partner, known for speed, responsiveness, and a high customer-touch business model. Think BIG...Think Microsize.